Migraine Diagnoses Among United States Employees from 2017 to 2022: Real World Evidence of Calcitonin Gene-Related Peptide Inhibitors (CGRPi) and Short-term Disability Utilization Jan 16, 2025
Real World Objectively Measured Productivity Losses of Employees with Migraines and the Use of Calcitonin Gene-Related Peptide Inhibitors (CGRPis) in United States Employees Oct 2, 2024
Characterizing Use and Productivity Losses Among United States Employees with Migraines Using Calcitonin Gene-Related Peptide inhibitors (CGRPis): 2017-2022 Oct 2, 2024
Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Headaches and Migraines Aug 2, 2022
Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Headaches and Migraines Apr 22, 2022
